Japanese Journal of Clinical Oncology, Vol 27, Issue 6 389-393, Copyright © 1997 by Foundation for Promotion of Cancer Research
M Watanabe, T Ushijima, T Shiraishi, R Yatani, J Shimazaki, T Kotake, T Sugimura and M Nagao
In order to determine the significance of androgen receptor (AR) gene
mutations for Japanese prostate cancers, we examined the entire coding
region, from exon A to H, in 36 primary lesions. Five in stage A, 12 in
stage B, six in stage C and 13 in stage D were subjected to PCR-SSCP
analysis for genomic DNA and nucleotide sequencing. Mutations were detected
in five samples (14%). Two in stage D and refractory to anti-androgen
treatment showed mis-sense mutations. The other three showed changes in the
length of the CAG repeat in exon A, with an expansion or a contraction of
one repeat unit. However, no association with changes in AR function was
indicated because they had not been refractory to hormone therapy. Since
these latter three tumors were associated with microsatellite instability,
the changes might have been the result of an impairment of mismatch repair.
This study indicates that AR gene mutations play a role, in only a subset
of prostate cancer patients, in a treatment-refractory state.
ORIGINAL ARTICLE
Genetic alterations of androgen receptor gene in Japanese human prostate cancer
Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. P. Zeegers, L. A.L.M. Kiemeney, A. M. Nieder, and H. Ostrer How Strong Is the Association Between CAG and GGN Repeat Length Polymorphisms in the Androgen Receptor Gene and Prostate Cancer Risk? Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1765 - 1771. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Buchanan, M. Yang, A. Cheong, J. M. Harris, R. A. Irvine, P. F. Lambert, N. L. Moore, M. Raynor, P. J. Neufing, G. A. Coetzee, et al. Structural and functional consequences of glutamine tract variation in the androgen receptor Hum. Mol. Genet., August 15, 2004; 13(16): 1677 - 1692. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Lamb, E. Puxeddu, N. Malik, D. L. Stenoien, R. Nigam, G. Y. Saleh, M. Mancini, N. L. Weigel, and M. Marcelli Molecular Analysis of the Androgen Receptor in Ten Prostate Cancer Specimens Obtained Before and After Androgen Ablation J Androl, March 1, 2003; 24(2): 215 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Krishnan, X.-Y. Zhao, S. Swami, L. Brive, D. M. Peehl, K. R. Ely, and D. Feldman A Glucocorticoid-Responsive Mutant Androgen Receptor Exhibits Unique Ligand Specificity: Therapeutic Implications for Androgen-Independent Prostate Cancer Endocrinology, May 1, 2002; 143(5): 1889 - 1900. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Buchanan, N. M. Greenberg, H. I. Scher, J. M. Harris, V. R. Marshall, and W. D. Tilley Collocation of Androgen Receptor Gene Mutations in Prostate Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1273 - 1281. [Abstract] [Full Text] |
||||
![]() |
M. Marcelli, M. Ittmann, S. Mariani, R. Sutherland, R. Nigam, L. Murthy, Y. Zhao, D. DiConcini, E. Puxeddu, A. Esen, et al. Androgen Receptor Mutations in Prostate Cancer Cancer Res., February 1, 2000; 60(4): 944 - 949. [Abstract] [Full Text] |
||||
![]() |
L. V. Nazareth, D. L. Stenoien, W. E. Bingman III, A. J. James, C. Wu, Y. Zhang, D. P. Edwards, M. Mancini, M. Marcelli, D. J. Lamb, et al. A C619Y Mutation in the Human Androgen Receptor Causes Inactivation and Mislocalization of the Receptor with Concomitant Sequestration of SRC-1 (Steroid Receptor Coactivator 1) Mol. Endocrinol., December 1, 1999; 13(12): 2065 - 2075. [Abstract] [Full Text] |
||||






